Key Insights

Highlights

Success Rate

84% trial completion

Published Results

19 trials with published results (16%)

Research Maturity

61 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

10.0%

12 terminated out of 120 trials

Success Rate

83.6%

-2.9% vs benchmark

Late-Stage Pipeline

23%

27 trials in Phase 3/4

Results Transparency

31%

19 of 61 completed with results

Key Signals

19 with results84% success12 terminated

Data Visualizations

Phase Distribution

89Total
Not Applicable (31)
P 1 (8)
P 2 (23)
P 3 (21)
P 4 (6)

Trial Status

Completed61
Recruiting17
Terminated12
Unknown9
Withdrawn7
Active Not Recruiting4

Trial Success Rate

83.6%

Benchmark: 86.5%

Based on 61 completed trials

Clinical Trials (120)

Showing 20 of 20 trials
NCT07607730Not ApplicableRecruitingPrimary

Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation

NCT07450664Enrolling By InvitationPrimary

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

NCT05939453Not ApplicableRecruitingPrimary

Impact of Bright Light Therapy on Prader-Willi Syndrome

NCT07348601Phase 2RecruitingPrimary

A Study of CSTI-500 in Patients With Prader-Willi Syndrome

NCT04257929Phase 2CompletedPrimary

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

NCT03848481Phase 2TerminatedPrimary

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

NCT06828861Phase 3Suspended

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

NCT02529085Not ApplicableCompletedPrimary

PWS European Blood Bank for Infants and Controls From 0 to 48 Months

NCT05791604Not ApplicableRecruitingPrimary

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

NCT07197034Phase 3Suspended

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

NCT07219485Phase 3Enrolling By InvitationPrimary

A Study of Pitolisant in Participants With Prader-Willi Syndrome

NCT06366464Phase 3RecruitingPrimary

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06740162Not ApplicableRecruiting

Physical Activity and Community EmPOWERment Project

NCT06772597Phase 2Active Not RecruitingPrimary

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

NCT05945576Recruiting

IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

NCT06573723Recruiting

Institutional Registry of Rare Diseases

NCT04697381Phase 3CompletedPrimary

Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS

NCT06239116Phase 1Recruiting

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT05938543Not ApplicableRecruitingPrimary

Cerebellar TMS and Satiety in Prader-Willi Syndrome

NCT07266324Phase 2Not Yet RecruitingPrimary

A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

Scroll to load more

Research Network

Activity Timeline